Product Description
MEN2312 is a potent and selective orally bioavailable KAT6A/B inhibitor. KAT6A/B belong to the MYST family of acetyltransferases (HAT) that acetylates histone H3K23 and non-histone proteins, such as p53 exerting an oncogenic role in several tumor types, including breast cancer, where KAT6A is frequently amplified/overexpressed. Inhibiting KAT6A, MEN2312 blocks the Estrogen receptor (ER) at the transcriptional level, giving it the potential to overcome resistance to endocrine therapies due to mutation or ligand-independent constitutive activation of ER. MEN2312 is being tested as single agent and in combination with SoC in metastatic Breast Cancer ER+/HER2- patients. (Sourced from: https://www.menarini.com/en-us/innovation-research/our-pipeline-and-products)
Mechanisms of Action: KAT6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|